Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte
- 27 November 2018
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 20 (1), 1-15
- https://doi.org/10.2174/1389450119666180405094046
Abstract
Glucocorticoids are widely used to treat varieties of allergic and autoimmune diseases, however, long-term application results in glucocorticoid-induced osteoporosis (GIOP). Inflammatory cytokines: tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) play important regulatory roles in bone metabolism, but their roles in GIOP remain largely unknown. Osteocytes can modulate the formation and function of both osteoblasts and osteoclasts, directly via gap junctions, or indirectly by transferring molecule signaling. Apoptotic osteocytes release RANKL, HMGB1 and pro-inflammatory cytokines to stimulate osteoclastogenesis. Moreover, osteocytes can secrete FGF23 to regulate bone metabolism. Exposure to high levels of GCs can drive osteocyte apoptosis and influence gap junctions, leading to bone loss. GCs treatment is regarded to produce more FGF23 to inhibit bone mineralization. GCs also disrupt the vascular to decrease osteocyte feasibility and mineral appositional rate, resulting in a decline in bone strength. Apoptotic bodies from osteocytes induced by GCs treatment can enhance production of TNF-α and IL-6. On the other hand, TNF-α and IL-6 show synergistic effects by altering osteocytes signaling towards osteoclasts and osteoblasts. In addition, TNF-α can induce osteocyte apoptosis and attribute to a worsened bone quality in GCs. IL-6 and osteocytes may interact with each other. Therefore, we hypothesize that GCs regulate osteocyteogenesis through TNF-α and IL-6, which are highly expressed around osteocyte undergoing apoptosis. In the present review, we summarized the roles of osteocytes in regulating osteoblasts and osteoclasts. Furthermore, the mechanism of GCs altered relationship between osteocytes and osteoblasts/osteoclasts. In addition, we discussed the roles of TNF-α and IL-6 in GIOP by modulating osteocytes. Lastly, we discussed the possibility of using pro-inflammatory signaling pathway as therapeutic targets to develop drugs for GIOP.Keywords
Funding Information
- The Chengdu Bureau of Science and Technology (2015-HM02-00042-SF, 2014-HM01-00382-SF)
- Ministry of Education of the People's Republic of China (MOE) (20130181110066)
- National Natural Science Foundation of China (81372110, 81572236, 81572639, 81370969, 81072190)
This publication has 144 references indexed in Scilit:
- Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populationsBone, 2012
- Osteocyte Signaling in BoneCurrent Osteoporosis Reports, 2012
- Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defectsBone, 2012
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodelingJournal of Bone and Mineral Research, 2010
- Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the β-catenin and PKA pathwaysJournal of Bone and Mineral Research, 2010
- Glucocorticoid-induced autophagy in osteocytesJournal of Bone and Mineral Research, 2010
- Osteocyte apoptosis and control of bone resorption following ovariectomy in miceBone, 2010
- Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularityBone, 2010
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006